Advisor Group Holdings, Inc. Aveo Pharmaceuticals, Inc. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$8.48 - $14.97 $9,073 - $16,017	-1,070 Reduced 65.4%	566 $8,000
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $469 - $619	71 Added 4.54%	1,636 $13,000
Q2 2022 Aug 10, 2022	SELL	$3.51 - $6.67 $2,193 - $4,168	-625 Reduced 28.54%	1,565 $10,000
Q1 2022 May 04, 2022	BUY	$3.15 - $6.01 $1,811 - $3,455	575 Added 35.6%	2,190 $12,000
Q3 2021 Nov 05, 2021	SELL	$5.12 - $6.89 $128 - $172	-25 Reduced 1.52%	1,615 $11,000
Q2 2021 Aug 02, 2021	SELL	$6.21 - $7.45 $1,639 - $1,966	-264 Reduced 13.87%	1,640 $11,000
Q1 2021 May 13, 2021	BUY	$5.97 - $15.28 $4,083 - $10,451	684 Added 56.07%	1,904 $14,000
Q4 2020 Feb 10, 2021	BUY	$5.08 - $6.68 $4,521 - $5,945	890 Added 269.7%	1,220 $7,000
Q3 2020 Nov 12, 2020	SELL	$4.16 - $6.26 $416 - $626	-100 Reduced 23.26%	330 $2,000
Q1 2020 May 18, 2020	BUY	$2.6 - $6.9 $1,118 - $2,967	430 New	430 $2,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.